Physician profile
Bijas Benjamin
NPI 1174880298
$5,292.02
in general payments reported to CMS, 2019-2025
54 companies · $700 in 2025
The $700 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $375 · 2020: $543 · 2021: $1,115 · 2022: $965 · 2023: $1,008 · 2024: $586 · 2025: $700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,293.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $678.34 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $395.55 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $375.90 | 2019-2025 | Farxiga, Airsupra |
| Abbott Laboratories | $285.48 | 2019-2025 | Freestyle Libre 3, Proclaim |
| Abbvie INC. | $278.46 | 2019-2025 | Qulipta, Synthroid, Ubrelvy |
| Merck Sharp & Dohme LLC | $218.49 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $179.90 | 2021-2025 | |
| Optos, INC. | $176.08 | 2021 | |
| Idorsia Pharmaceuticals US INC | $171.86 | 2022-2024 | Quviviq |
| Itamar Medical INC | $165.81 | 2022-2024 | Watchpatone |
| Zimmer Biomet Holdings, INC. | $165.01 | 2022-2024 | Cellentra |
| Glaxosmithkline, LLC. | $159.65 | 2019-2023 | Shingrix, Arexvy |
| Daiichi Sankyo INC. | $158.31 | 2020-2022 | |
| Amgen INC. | $126.99 | 2020-2025 | Krystexxa, Otezla, Repatha |
| Pfizer INC. | $118.10 | 2023-2024 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bijas Benjamin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.